Literature DB >> 20570963

FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis.

Paola Maderna1, David C Cottell, Tiina Toivonen, Neil Dufton, Jesmond Dalli, Mauro Perretti, Catherine Godson.   

Abstract

Lipoxins (LXs) are endogenously produced eicosanoids with well-described anti-inflammatory and proresolution activities, stimulating nonphlogistic phagocytosis of apoptotic cells by macrophages. LXA(4) and the glucocorticoid-derived annexin A1 peptide (Ac2-26) bind to a common G-protein-coupled receptor, termed FPR2/ALX. However, direct evidence of the involvement of FPR2/ALX in the anti-inflammatory and proresolution activity of LXA(4) is still to be investigated. Here we describe FPR2/ALX trafficking in response to LXA(4) and Ac2-26 stimulation. We have transfected cells with HA-tagged FPR2/ALX and studied receptor trafficking in unstimulated, LXA(4) (1-10 nM)- and Ac2-26 (30 μM)-treated cells using multiple approaches that include immunofluorescent confocal microscopy, immunogold labeling of cryosections, and ELISA and investigated receptor trafficking in agonist-stimulated phagocytosis. We conclude that PKC-dependent internalization of FPR2/ALX is required for phagocytosis. Using bone marrow-derived macrophages (BMDMs) from mice in which the FPR2/ALX ortholog Fpr2 had been deleted, we observed the nonredundant function for this receptor in LXA(4) and Ac2-26 stimulated phagocytosis of apoptotic neutrophils. LXA(4) stimulated phagocytosis 1.7-fold above basal (P<0.001) by BMDMs from wild-type mice, whereas no effect was found on BMDMs from Fpr2(-/-) mice. Similarly, Ac2-26 stimulates phagocytosis by BMDMs from wild-type mice 1.5-fold above basal (P<0.05). However, Ac2-26 failed to stimulate phagocytosis by BMDMs isolated from Fpr2(-/-) mice relative to vehicle. These data reveal novel and complex mechanisms of the FPR2/ALX receptor trafficking and functionality in the resolution of inflammation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20570963      PMCID: PMC4338542          DOI: 10.1096/fj.10-159913

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  52 in total

Review 1.  Phagocytosis of apoptotic cells and the resolution of inflammation.

Authors:  Paola Maderna; Catherine Godson
Journal:  Biochim Biophys Acta       Date:  2003-11-20

Review 2.  Resolution of inflammation: the beginning programs the end.

Authors:  Charles N Serhan; John Savill
Journal:  Nat Immunol       Date:  2005-12       Impact factor: 25.606

3.  Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine.

Authors:  O Soyombo; B W Spur; T H Lee
Journal:  Allergy       Date:  1994-04       Impact factor: 13.146

Review 4.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

5.  The role of beta-arrestins in the formyl peptide receptor-like 1 internalization and signaling.

Authors:  Emilie Huet; François Boulay; Sophie Barral; Marie-Josèphe Rabiet
Journal:  Cell Signal       Date:  2007-05-29       Impact factor: 4.315

Review 6.  Annexin 1 and the biology of the neutrophil.

Authors:  Mauro Perretti; Roderick John Flower
Journal:  J Leukoc Biol       Date:  2004-02-13       Impact factor: 4.962

Review 7.  Lipoxins: endogenous regulators of inflammation.

Authors:  Blaithin McMahon; Catherine Godson
Journal:  Am J Physiol Renal Physiol       Date:  2004-02

8.  Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation.

Authors:  N Chiang; I M Fierro; K Gronert; C N Serhan
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

9.  A technique for ultracryotomy of cell suspensions and tissues.

Authors:  K T Tokuyasu
Journal:  J Cell Biol       Date:  1973-05       Impact factor: 10.539

10.  Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation.

Authors:  Mauro Perretti; Roderick J Flower; Neil Dufton; Robert Hannon; Vincenzo Brancaleone; Jesmond Dalli; Hetal B Patel; Mohini Gray; Fulvio D'Acquisto; Julia C Buckingham
Journal:  J Immunol       Date:  2010-01-27       Impact factor: 5.422

View more
  77 in total

1.  Atheroma Niche-Responsive Nanocarriers for Immunotherapeutic Delivery.

Authors:  Erica B Peters; Nick D Tsihlis; Mark R Karver; Stacey M Chin; Bruno Musetti; Benjamin T Ledford; Edward M Bahnson; Samuel I Stupp; Melina R Kibbe
Journal:  Adv Healthc Mater       Date:  2019-01-08       Impact factor: 9.933

Review 2.  The resolution of inflammation: the devil in the flask and in the details.

Authors:  Charles N Serhan
Journal:  FASEB J       Date:  2011-05       Impact factor: 5.191

3.  Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature.

Authors:  Vincenzo Brancaleone; Jesmond Dalli; Stefania Bena; Roderick J Flower; Giuseppe Cirino; Mauro Perretti
Journal:  J Immunol       Date:  2011-03-11       Impact factor: 5.422

Review 4.  Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis: JACC Macrophage in CVD Series (Part 2).

Authors:  Kathryn J Moore; Simon Koplev; Edward A Fisher; Ira Tabas; Johan L M Björkegren; Amanda C Doran; Jason C Kovacic
Journal:  J Am Coll Cardiol       Date:  2018-10-30       Impact factor: 24.094

5.  Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs.

Authors:  Sriram Krishnamoorthy; Antonio Recchiuti; Nan Chiang; Gabrielle Fredman; Charles N Serhan
Journal:  Am J Pathol       Date:  2012-03-23       Impact factor: 4.307

6.  ALX receptor ligands define a biochemical endotype for severe asthma.

Authors:  Isabell Ricklefs; Ioanna Barkas; Melody G Duvall; Manuela Cernadas; Nicole L Grossman; Elliot Israel; Eugene R Bleecker; Mario Castro; Serpil C Erzurum; John V Fahy; Benjamin M Gaston; Loren C Denlinger; David T Mauger; Sally E Wenzel; Suzy A Comhair; Andrea M Coverstone; Merritt L Fajt; Annette T Hastie; Mats W Johansson; Michael C Peters; Brenda R Phillips; Bruce D Levy
Journal:  JCI Insight       Date:  2017-07-20

Review 7.  Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7.

Authors:  Magnus Bäck; William S Powell; Sven-Erik Dahlén; Jeffrey M Drazen; Jilly F Evans; Charles N Serhan; Takao Shimizu; Takehiko Yokomizo; G Enrico Rovati
Journal:  Br J Pharmacol       Date:  2014-07-12       Impact factor: 8.739

8.  Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.

Authors:  Frances T Hakim; Sarfraz Memon; Ping Jin; Matin M Imanguli; Huan Wang; Najibah Rehman; Xiao-Yi Yan; Jeremy Rose; Jacqueline W Mays; Susan Dhamala; Veena Kapoor; William Telford; John Dickinson; Sean Davis; David Halverson; Haley B Naik; Kristin Baird; Daniel Fowler; David Stroncek; Edward W Cowen; Steven Z Pavletic; Ronald E Gress
Journal:  J Immunol       Date:  2016-09-30       Impact factor: 5.422

9.  Gene expression signature-based approach identifies a pro-resolving mechanism of action for histone deacetylase inhibitors.

Authors:  T Montero-Melendez; J Dalli; M Perretti
Journal:  Cell Death Differ       Date:  2012-12-07       Impact factor: 15.828

Review 10.  The role of lipoxin A4 in endometrial biology and endometriosis.

Authors:  G O Canny; B A Lessey
Journal:  Mucosal Immunol       Date:  2013-03-13       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.